Your session is about to expire
← Back to Search
Comparison of the Alpha-2 Agonists for Prevention of Intraocular Pressure Elevation After Selective Laser Trabeculoplasty
N/A
Waitlist Available
Led By Vladimir S Yakopson, MD
Research Sponsored by Walter Reed Army Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
Approved for 5 Other Conditions
All Individual Drugs Already Approved
No Placebo-Only Group
Summary
The purpose of the study is to compare the safety and efficacy of two drops used to lower eye pressure when given prior to a glaucoma laser procedure.
Eligible Conditions
- Glaucoma
- Ocular Hypertension
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
Treatment Details
Awards & Highlights
Approved for 5 Other Conditions
This treatment demonstrated efficacy for 5 other conditions.
All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Active Control
Group I: AActive Control1 Intervention
Eyes receiving Brimonidine 0.1% (Alphagan) prior to SLT
Group II: IActive Control1 Intervention
Eyes receiving Apraclonidine 0.5% (Iopidine) prior to SLT
Find a Location
Who is running the clinical trial?
Walter Reed Army Medical CenterLead Sponsor
69 Previous Clinical Trials
20,896 Total Patients Enrolled
Vladimir S Yakopson, MDPrincipal InvestigatorWalter Reed AMC